IL1B and idiopathic pulmonary fibrosis: For example, nintedanib treating idiopathic pulmonary fibrosis can reduce the expression of proinflammatory factors IL-1β, IL-6, and TNF-ɑ by downregulating the PI3K/Akt/mTOR pathway [51].